## SAFETY DATA SHEET



ALPOCRYL RF 5364-15 - All variants

# SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Product name : ALPOCRYL RF 5364-15 - All variants

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Product use : Paint.

#### 1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

e-mail address of person : Prod-safe@teknos.com

responsible for this SDS

**National contact** 

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

#### 1.4 Emergency telephone number

**National advisory body/Poison Centre** 

Telephone number : National Poisons Information Centre: 01 809 2566

#### **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

**Product definition**: Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 3, H226 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H336 STOT RE 2, H373

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

#### 2.2 Label elements

Hazard pictograms :







Signal word : Warning

**Hazard statements** : H226 - Flammable liquid and vapour.

H315 - Causes skin irritation.

H319 - Causes serious eye irritation.

H336 - May cause drowsiness or dizziness.

H373 - May cause damage to organs through prolonged or repeated exposure.

**Precautionary statements** 

**Prevention**: P280 - Wear protective gloves. Wear eye or face protection.

P210 - Keep away from heat, hot surfaces, sparks, open flames and other ignition

Label No: 68362

sources. No smoking.

P260 - Do not breathe vapour.

Date of issue/Date of revision: 20/12/2023Date of previous issue: No previous validationVersion: 11/18

#### SECTION 2: Hazards identification

Response

: P314 - Get medical advice/attention if you feel unwell.

**Storage** 

: P403 + P233 - Store in a well-ventilated place. Keep container tightly closed.

**Disposal** 

: P501 - Dispose of contents and container in accordance with all local, regional,

national and international regulations.

**Hazardous ingredients** 

Supplemental label

elements

: Contains: n-Butyl acetate and Xylene

: Contains Methyl methacrylate and N,N,4-trimethylpiperazine-1-ethylamine. May

produce an allergic reaction.

Warning! Hazardous respirable droplets may be formed when sprayed. Do not

breathe spray or mist.

**Annex XVII - Restrictions** on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

#### 2.3 Other hazards

**Product meets the criteria** for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII

: This mixture does not contain any substances that are assessed to be a PBT or a

vPvB.

Other hazards which do not result in classification

: None known.

## SECTION 3: Composition/information on ingredients

#### Mixture 3.2 Mixtures

| Product/ingredient name         | Identifiers  | %         | Classification   | Specific Conc.<br>Limits, M-factors<br>and ATEs                             | Туре    |
|---------------------------------|--|-----------|--|---|---------|
| n-Butyl acetate                 | REACH #:<br>01-2119485493-29<br>EC: 204-658-1<br>CAS: 123-86-4<br>Index: 607-025-00-1  | ≥25 - ≤50 | Flam. Liq. 3, H226<br>STOT SE 3, H336<br>EUH066  | -   | [1] [2] |
| titanium dioxide                | REACH #:<br>01-2119489379-17<br>EC: 236-675-5<br>CAS: 13463-67-7                       | ≥10 - ≤25 | Carc. 2, H351<br>(inhalation)  | -   | [1] [*] |
| Xylene                          | REACH #:<br>01-2119488216-32<br>EC: 215-535-7<br>CAS: 1330-20-7<br>Index: 601-022-00-9 | ≥10 - <20 | Flam. Liq. 3, H226<br>Acute Tox. 4, H312<br>Acute Tox. 4, H332<br>Skin Irrit. 2, H315<br>Eye Irrit. 2, H319<br>STOT SE 3, H335<br>STOT RE 2, H373<br>(oral, inhalation)<br>Asp. Tox. 1, H304 | ATE [Dermal] =<br>1100 mg/kg<br>ATE [Inhalation<br>(vapours)] = 11 mg/<br>I | [1] [2] |
| 2-Methoxy-1-methylethyl acetate | REACH #:<br>01-2119475791-29<br>EC: 203-603-9<br>CAS: 108-65-6<br>Index: 607-195-00-7  | ≤3        | Flam. Liq. 3, H226   | -   | [2]     |
| Ethylbenzene                    | REACH #:<br>01-2119489370-35<br>EC: 202-849-4<br>CAS: 100-41-4<br>Index: 601-023-00-4  | ≤3        | Flam. Liq. 2, H225<br>Acute Tox. 4, H332<br>STOT RE 2, H373<br>(hearing organs) (oral,<br>inhalation)  | ATE [Inhalation<br>(vapours)] = 11 mg/                                      | [1] [2] |

Date of issue/Date of revision : 20/12/2023 Version :1 2/18 Date of previous issue : No previous validation

Label No: 68362

#### SECTION 3: Composition/information on ingredients Asp. Tox. 1, H304 2-butoxyethyl acetate REACH #: ≤3 Acute Tox. 4, H312 ATE [Dermal] = [1] [2] 01-2119475112-47 Acute Tox. 4, H332 1500 mg/kg EC: 203-933-3 ATE [Inhalation (vapours)] = 11 mg/ CAS: 112-07-2 Index: 607-038-00-2 REACH #: Flam. Liq. 2, H225 Methyl methacrylate ≤0.3 [1] [2] 01-2119452498-28 Skin Irrit. 2, H315 EC: 201-297-1 Skin Sens. 1, H317 STOT SE 3, H335 CAS: 80-62-6 Index: 607-035-00-6 N,N,4-trimethylpiperazine-EC: 203-183-7 ≤0.3 Acute Tox. 4, H302 ATE [Oral] = 500 [1] 1-ethylamine CAS: 104-19-8 Acute Tox. 3, H311 mg/kg Skin Corr. 1B, H314 ATE [Dermal] = Eye Dam. 1, H318 300 mg/kg Skin Sens. 1, H317 Aquatic Chronic 3, H412 See Section 16 for the full text of the H

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

- [1] Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit
- [\*] The classification as a carcinogen by inhalation applies only to mixtures placed on the market in powder form containing 1% or more of titanium dioxide particles with aerodynamic diameter ≤ 10 µm not bound within a matrix.

Occupational exposure limits, if available, are listed in Section 8.

#### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

**Eye contact** 

: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.

statements declared

above.

Inhalation

: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If necessary, call a poison center or physician. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

**Skin contact** 

: Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Continue to rinse for at least 10 minutes. Get medical attention. Wash clothing before reuse. Clean shoes thoroughly before reuse.

Ingestion

: Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. If necessary, call a poison center or physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

Date of issue/Date of revision : 20/12/2023 Date of previous issue Version :1 : No previous validation 3/18 **Label No: 68362** 

#### **SECTION 4: First aid measures**

#### **Protection of first-aiders**

: No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation.

#### 4.2 Most important symptoms and effects, both acute and delayed

#### Over-exposure signs/symptoms

**Eye contact** : Adverse symptoms may include the following:

pain or irritation watering redness

**Inhalation** : Adverse symptoms may include the following:

nausea or vomiting

headache

drowsiness/fatigue dizziness/vertigo unconsciousness

**Skin contact**: Adverse symptoms may include the following:

irritation redness

**Ingestion**: No specific data.

#### 4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician : In case of inhalation of decomposition products in a fire, symptoms may be delayed.

The exposed person may need to be kept under medical surveillance for 48 hours.

**Specific treatments**: No specific treatment.

## **SECTION 5: Firefighting measures**

#### 5.1 Extinguishing media

Suitable extinguishing

media

: Use dry chemical, CO2, water spray (fog) or foam.

Unsuitable extinguishing

media

: Do not use water jet.

#### 5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture

: Flammable liquid and vapour. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion.

Hazardous combustion products

: Decomposition products may include the following materials:

carbon dioxide carbon monoxide nitrogen oxides metal oxide/oxides

#### 5.3 Advice for firefighters

Special protective actions for fire-fighters

: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.

Special protective equipment for fire-fighters

: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

Label No: 68362

Date of issue/Date of revision : 20/12/2023 Date of previous issue : No previous validation Version : 1 4/18

#### SECTION 6: Accidental release measures

#### 6.1 Personal precautions, protective equipment and emergency procedures

#### For non-emergency personnel

: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.

#### For emergency responders:

If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

#### 6.2 Environmental precautions

: Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

#### 6.3 Methods and material for containment and cleaning up

### **Small spill**

: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

#### Large spill

: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with noncombustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product.

#### 6.4 Reference to other sections

: See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

## SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 7.1 Precautions for safe handling

#### **Protective measures**

: Put on appropriate personal protective equipment (see Section 8). Do not breathe vapour or mist. Do not ingest. Avoid contact with eyes, skin and clothing. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.

### Advice on general occupational hygiene

Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

#### 7.2 Conditions for safe storage, including any incompatibilities

Date of issue/Date of revision : 20/12/2023 Version :1 5/18 Date of previous issue

ALPOCRYL RF 5364-15 - All variants

Label No: 68362

## **SECTION 7: Handling and storage**

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Eliminate all ignition sources. Separate from oxidising materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.

#### Seveso Directive - Reporting thresholds

#### **Danger criteria**

|     | Notification and MAPP threshold | Safety report threshold |
|-----|---------------------------------|-------------------------|
| P5c | 5000 tonne                      | 50000 tonne             |

#### 7.3 Specific end use(s)

Recommendations : Not available.

Industrial sector specific : Not available.

solutions

## **SECTION 8: Exposure controls/personal protection**

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

#### 8.1 Control parameters

#### **Occupational exposure limits**

| Product/ingredient name         | Exposure limit values   |
|---------------------------------|---|
| n-Butyl acetate                 | NAOSH (Ireland, 5/2021). Notes: EU derived Occupational           |
|                                 | Exposure Limit Values   |
|                                 | OELV-8hr: 50 ppm 8 hours.   |
|                                 | OELV-8hr: 241 mg/m³ 8 hours.                                      |
|                                 | OELV-15min: 150 ppm 15 minutes.                                   |
|                                 | OELV-15min: 723 mg/m³ 15 minutes.                                 |
| Xylene                          | NAOSH (Ireland, 5/2021). [xylene mixed isomers] Absorbed          |
|                                 | through skin. Notes: EU derived Occupational Exposure Limit       |
|                                 | Values  |
|                                 | OELV-8hr: 50 ppm 8 hours.   |
|                                 | OELV-8hr: 221 mg/m³ 8 hours.                                      |
|                                 | OELV-15min: 100 ppm 15 minutes.                                   |
|                                 | OELV-15min: 442 mg/m³ 15 minutes.                                 |
| 2-Methoxy-1-methylethyl acetate | NAOSH (Ireland, 5/2021). Absorbed through skin. Notes: EU         |
|                                 | derived Occupational Exposure Limit Values                        |
|                                 | OELV-8hr: 50 ppm 8 hours.   |
|                                 | OELV-8hr: 275 mg/m³ 8 hours.                                      |
|                                 | OELV-15min: 100 ppm 15 minutes.                                   |
|                                 | OELV-15min: 550 mg/m³ 15 minutes.                                 |
| Ethylbenzene                    | NAOSH (Ireland, 5/2021). Absorbed through skin. Notes: EU         |
|                                 | derived Occupational Exposure Limit Values                        |
|                                 | OELV-8hr: 100 ppm 8 hours.  |
|                                 | OELV-8hr: 442 mg/m³ 8 hours.                                      |
|                                 | OELV-15min: 200 ppm 15 minutes.                                   |
|                                 | OELV-15min: 884 mg/m³ 15 minutes.                                 |
| 2-butoxyethyl acetate           | NAOSH (Ireland, 5/2021). Absorbed through skin. Notes: EU         |
|                                 | derived Occupational Exposure Limit Values                        |
|                                 | OELV-8hr: 20 ppm 8 hours.   |
|                                 | OELV-8hr: 133 mg/m³ 8 hours. OELV-15min: 50 ppm 15 minutes.       |
|                                 | OELV-15min: 30 ppm 13 minutes.  OELV-15min: 333 mg/m³ 15 minutes. |
| Methyl methacrylate             | NAOSH (Ireland, 5/2021). Sensitization potential. Notes: EU       |
|                                 | derived Occupational Exposure Limit Values                        |
|                                 | OELV-8hr: 50 ppm 8 hours.   |
|                                 | OELV-15min: 100 ppm 15 minutes.                                   |
|                                 | OLL V-10min. 100 ppm 10 minutes.                                  |

Date of issue/Date of revision: 20/12/2023Date of previous issue: No previous validationVersion: 16/18ALPOCRYL RF 5364-15 - All variantsLabel No :68362

#### **Biological exposure indices**

| Product/ingredient name | Exposure indices   |
|-------------------------|--|
| Xylene                  | NAOSH (Ireland, 1/2011) [Xylene] BMGV: 1.5 g/g creatinine, methylhippuric acids [in urine]. Sampling time: end of shift - As soon as possible after exposure ceases.   |
| Ethylbenzene            | NAOSH (Ireland, 1/2011)  BMGV: Semi-quantitative, the biological analyte is an indicator of exposure to the substance but the quantitative interpretation of the measurement is ambiguous. These analytes should be used as a screening test if a quantitative test is not practical; or as a confirmatory test if the quantitative test is not specific and the origin of the determinant is in question., ethylbenzene [in endexhaled air]. Sampling time: not critical.  BMGV: 0.7 g/g creatinine [Semi-quantitative, the biological analyte is an indicator of exposure to the substance but the quantitative interpretation of the measurement is ambiguous. These analytes should be used as a screening test if a quantitative test is not practical; or as a confirmatory test if the quantitative test is not specific and the origin of the determinant is in question.], mandelic acid and phenylglyoxylic acid [in urine]. Sampling time: end of shift at end of workweek. |

# procedures

**Recommended monitoring**: Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

#### **DNELs/DMELs**

| Product/ingredient name | Type | Exposure          | Value                  | <b>Population</b> | Effects  |
|-------------------------|------|-------------------|------------------------|-------------------|----------|
| n-Butyl acetate         | DNEL | Short term Oral   | 2 mg/kg                | General           | Systemic |
| •                       |      |                   | bw/day                 | population        |          |
|                         | DNEL | Long term Oral    | 2 mg/kg                | General           | Systemic |
|                         |      |                   | bw/day                 | population        |          |
|                         | DNEL | Short term Dermal | 6 mg/kg                | General           | Systemic |
|                         |      |                   | bw/day                 | population        |          |
|                         | DNEL | Short term Dermal | 11 mg/kg               | Workers           | Systemic |
|                         |      |                   | bw/day                 |                   | •        |
|                         | DNEL | Long term         | 35.7 mg/m <sup>3</sup> | General           | Local    |
|                         |      | Inhalation        | _                      | population        |          |
|                         | DNEL | Short term        | 300 mg/m <sup>3</sup>  | General           | Local    |
|                         |      | Inhalation        |                        | population        |          |
|                         | DNEL | Short term        | 300 mg/m <sup>3</sup>  | General           | Systemic |
|                         |      | Inhalation        |                        | population        |          |
|                         | DNEL | Long term         | 300 mg/m <sup>3</sup>  | Workers           | Local    |
|                         |      | Inhalation        |                        |                   |          |
|                         | DNEL | Short term        | 600 mg/m <sup>3</sup>  | Workers           | Local    |
|                         |      | Inhalation        |                        |                   |          |
|                         | DNEL | Short term        | 600 mg/m <sup>3</sup>  | Workers           | Systemic |
|                         |      | Inhalation        |                        |                   |          |
|                         | DNEL | Long term Dermal  | 3.4 mg/kg              | General           | Systemic |
|                         |      |                   | bw/day                 | population        |          |
|                         | DNEL | Long term Dermal  | 7 mg/kg                | Workers           | Systemic |
|                         |      |                   | bw/day                 |                   |          |
|                         | DNEL | Long term         | 12 mg/m³               | General           | Systemic |
|                         |      | Inhalation        |                        | population        |          |
|                         | DNEL | Long term         | 48 mg/m³               | Workers           | Systemic |

Version :1 Date of issue/Date of revision : 20/12/2023 Date of previous issue : No previous validation 7/18 **Label No** :68362

|                                   |        | _                       |                        |                       |   |
|-----------------------------------|--------|-------------------------|------------------------|-----------------------|---|
| Xylene                            | DNEL   | Inhalation<br>Long term | 65.3 mg/m³             | General               | Local                                   |
| Aylono                            | DITLL  | Inhalation              | co.o mg/m              | population            | Local                                   |
|                                   | DNEL   | Short term              | 260 mg/m <sup>3</sup>  | General               | Local                                   |
|                                   | DNE    | Inhalation              | 000                    | population            | 0                                       |
|                                   | DNEL   | Short term              | 260 mg/m <sup>3</sup>  | General               | Systemic                                |
|                                   | DNEL   | Inhalation<br>Long term | 221 mg/m³              | population<br>Workers | Local                                   |
|                                   | DINLL  | Inhalation              | 22 i ilig/ili          | VVOIREIS              | Local                                   |
|                                   | DNEL   | Long term Oral          | 12.5 mg/               | General               | Systemic                                |
|                                   |        | 3                       | kg bw/day              | population            |   |
|                                   | DNEL   | Long term               | 65.3 mg/m <sup>3</sup> |                       | Systemic                                |
|                                   |        | Inhalation              |                        | population            |   |
|                                   | DNEL   | Long term Dermal        | 125 mg/kg              | General               | Systemic                                |
|                                   | DNEI   | Lang tarm Darmal        | bw/day                 | population            | Cymtamia                                |
|                                   | DNEL   | Long term Dermal        | 212 mg/kg<br>bw/day    | Workers               | Systemic                                |
|                                   | DNEL   | Long term               | 221 mg/m <sup>3</sup>  | Workers               | Systemic                                |
|                                   | DITLL  | Inhalation              | 2211119/111            | Workoro               | Cycloniic                               |
|                                   | DNEL   | Short term              | 442 mg/m <sup>3</sup>  | Workers               | Local                                   |
|                                   |        | Inhalation              | J                      |                       |   |
|                                   | DNEL   | Short term              | 442 mg/m <sup>3</sup>  | Workers               | Systemic                                |
| 0.14.41                           | DAIE:  | Inhalation              | 00 / 3                 | 0                     | Land                                    |
| 2-Methoxy-1-methylethyl acetate   | DNEL   | Long term<br>Inhalation | 33 mg/m³               | General               | Local                                   |
|                                   | DNEL   | Long term               | 33 mg/m³               | population<br>General | Systemic                                |
|                                   | DINLL  | Inhalation              | 33 mg/m                | population            | Systemic                                |
|                                   | DNEL   | Long term Oral          | 36 mg/kg               | General               | Systemic                                |
|                                   |        |                         | bw/day                 | population            | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, |
|                                   | DNEL   | Long term               | 275 mg/m <sup>3</sup>  | Workers               | Systemic                                |
|                                   |        | Inhalation              |                        | _                     |   |
|                                   | DNEL   | Long term Dermal        | 320 mg/kg              | General               | Systemic                                |
|                                   | DNEL   | Short term              | bw/day<br>550 mg/m³    | population<br>Workers | Local                                   |
|                                   | DIVEL  | Inhalation              | 330 mg/m               | VVOIKEIS              | LUCAI                                   |
|                                   | DNEL   | Long term Dermal        | 796 mg/kg              | Workers               | Systemic                                |
|                                   |        | J                       | bw/day                 |                       |   |
| Ethylbenzene                      | DNEL   | Long term Oral          | 1.6 mg/kg              | General               | Systemic                                |
|                                   | DAIEI  |                         | bw/day                 | population            |   |
|                                   | DNEL   | Long term               | 15 mg/m³               | General               | Systemic                                |
|                                   | DNEL   | Inhalation<br>Long term | 77 mg/m³               | population<br>Workers | Systemic                                |
|                                   | DIVLL  | Inhalation              | 77 mg/m                | VVOIRCIS              | Oysternio                               |
|                                   | DNEL   | Long term Dermal        | 180 mg/kg              | Workers               | Systemic                                |
|                                   |        |                         | bw/day                 |                       |   |
|                                   | DNEL   | Short term              | 293 mg/m <sup>3</sup>  | Workers               | Local                                   |
|                                   | חוארי  | Inhalation              | 110 malas              | Morkers               | Local                                   |
|                                   | DMEL   | Long term<br>Inhalation | 442 mg/m³              | Workers               | Local                                   |
|                                   | DMEL   | Short term              | 884 mg/m³              | Workers               | Systemic                                |
|                                   |        | Inhalation              | J                      |                       |   |
| 2-butoxyethyl acetate             | DNEL   | Long term Oral          | 8.6 mg/kg              | General               | Systemic                                |
|                                   | 5.151  |                         | bw/day                 | population            |   |
|                                   | DNEL   | Short term Oral         | 36 mg/kg               | General               | Systemic                                |
|                                   | DNEL   | Short term Dermal       | bw/day<br>72 mg/kg     | population<br>General | Systemic                                |
|                                   | PINEL  | Short term Dermal       | bw/day                 | population            | Cysternio                               |
|                                   | DNEL   | Long term               | 80 mg/m <sup>3</sup>   | General               | Systemic                                |
|                                   |        | Inhalation              |                        | population            |   |
|                                   | DNEL   | Long term Dermal        | 102 mg/kg              | General               | Systemic                                |
|                                   | ראורי  | Chart tarms Dames       | bw/day                 | population            | Cyatansia                               |
|                                   | DNEL   | Short term Dermal       | 120 mg/kg<br>bw/day    | Workers               | Systemic                                |
|                                   | DNEL   | Long term               | 133 mg/m³              | Workers               | Systemic                                |
|                                   |        | Inhalation              |                        |                       |   |
|                                   | DNEL   | Long term Dermal        | 169 mg/kg              | Workers               | Systemic                                |
| to of icous/Data of revision 20/1 | 2/2022 | <u> </u>                |                        | ious validation Va    | roion 11 9/19                           |

Date of issue/Date of revision : 20/12/2023 Date of previous issue 8/18 : No previous validation Version :1 **Label No** :68362

| <u> </u>                              | •     | •                       |                        |                |           |
|---------------------------------------|-------|-------------------------|------------------------|----------------|-----------|
|                                       |       |                         | bw/day                 |                |           |
|                                       | DNEL  | Short term              | 200 mg/m <sup>3</sup>  | General        | Local     |
|                                       |       | Inhalation              |                        | population     |           |
|                                       | DNEL  | Short term              | 333 mg/m <sup>3</sup>  | Workers        | Local     |
|                                       |       | Inhalation              |                        |                |           |
| Methyl methacrylate                   | DNEL  | Long term Oral          | 8.2 mg/kg              | General        | Systemic  |
|                                       |       |                         | bw/day                 | population     |           |
|                                       | DNEL  | Short term              | 208 mg/m <sup>3</sup>  | General        | Local     |
|                                       |       | Inhalation              |                        | population     |           |
|                                       | DNEL  | Short term              | 416 mg/m <sup>3</sup>  | Workers        | Local     |
|                                       |       | Inhalation              |                        |                |           |
|                                       | DNEL  | Short term Dermal       | 1.5 mg/cm <sup>2</sup> |                | Local     |
|                                       |       |                         |                        | population     |           |
|                                       | DNEL  | Long term Dermal        | 1.5 mg/cm <sup>2</sup> | General        | Local     |
|                                       |       |                         |                        | population     |           |
|                                       | DNEL  | Short term Dermal       | 1.5 mg/cm <sup>2</sup> | Workers        | Local     |
|                                       | DNEL  | Long term Dermal        | 1.5 mg/cm <sup>2</sup> | Workers        | Local     |
|                                       | DNEL  | Long term Dermal        | 8.2 mg/kg              | General        | Systemic  |
|                                       |       |                         | bw/day                 | population     |           |
|                                       | DNEL  | Long term Dermal        | 13.67 mg/              | Workers        | Systemic  |
|                                       |       |                         | kg bw/day              |                |           |
|                                       | DNEL  | Long term               | 74.3 mg/m <sup>3</sup> |                | Systemic  |
|                                       | DATE  | Inhalation              | 404 / 2                | population     |           |
|                                       | DNEL  | Long term               | 104 mg/m <sup>3</sup>  | General        | Local     |
|                                       | DATE  | Inhalation              | 000                    | population     | 1 1       |
|                                       | DNEL  | Long term               | 208 mg/m <sup>3</sup>  | Workers        | Local     |
|                                       | DAIEI | Inhalation              | 040 4                  | \\/            | 0         |
|                                       | DNEL  | Long term               | 348.4 mg/              | Workers        | Systemic  |
| NI NI 4 twice attended to a version a | DNIEL | Inhalation              | m <sup>3</sup>         | VV/ a ml ca ma | Cuetamaia |
| N,N,4-trimethylpiperazine-            | DNEL  | Long term Dermal        | 0.167 mg/              | Workers        | Systemic  |
| 1-ethylamine                          | DNIEL | Long torm               | kg bw/day              | Morkoro        | Cuetomie  |
|                                       | DNEL  | Long term<br>Inhalation | 0.59 mg/m <sup>3</sup> | vvorkers       | Systemic  |
|                                       |       | mnalation               |                        |                |           |

#### **PNECs**

No PNECs available

#### 8.2 Exposure controls

Appropriate engineering controls

: Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapour or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.

#### **Individual protection measures**

**Hygiene measures** 

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

**Eye/face protection** 

: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles.

# Skin protection Hand protection

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.

Label No: 68362

Date of issue/Date of revision : 20/12/2023 Date of previous issue : No previous validation Version : 1 9/18

Recommendations: Wear suitable gloves tested to EN374.

Nitrile gloves. thickness > 0.3 mm < 1 hour (breakthrough time):

1 - 4 hours (breakthrough time): 4H / Silver Shield® gloves.

**Body protection** 

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods.

Other skin protection

Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection

: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Filter type:

Filter type (spray application):

**Environmental exposure** controls

Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

## SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

#### 9.1 Information on basic physical and chemical properties

**Appearance** 

**Physical state** : Liquid. Colour Various **Odour** : Slight : Not available. **Odour threshold** 

Initial boiling point and

Ingredient name

Melting point/freezing point

boiling range

n-Butyl acetate

Ethylbenzene

Not available.

°C °F Method **OECD 103** 126 258.8 136.1 277 **OECD 104** 

**Flammability** : Not available. Lower and upper explosion Lower: 0.8% limit Upper: 7.6%

: Closed cup: 27°C (80.6°F) Flash point

**Auto-ignition temperature** 

| Ingredient name                 | °C  | °F    | Method    |
|---------------------------------|-----|-------|-----------|
| 2-Methoxy-1-methylethyl acetate | 333 | 631.4 | DIN 51794 |
| 2-butoxyethyl acetate           | 340 | 644   |           |

**Decomposition temperature** : Not available. pΗ : Not applicable. **Viscosity** Not available.

Solubility(ies)

Not available.

Solubility in water : Not available.

Date of issue/Date of revision : 20/12/2023 10/18 Date of previous issue : No previous validation Version :1 Label No: 68362

## SECTION 9: Physical and chemical properties

Partition coefficient: n-octanol/ : Not applicable.

water

Vapour pressure

|                 | Vapour Pressure at 20°C |     |                | Va    | re at 50°C |        |
|-----------------|-------------------------|-----|----------------|-------|------------|--------|
| Ingredient name | mm Hg                   | kPa | Method         | mm Hg | kPa        | Method |
| n-Butyl acetate | 11.25096                | 1.5 | DIN EN 13016-2 |       |            |        |
| Ethylbenzene    | 9.30076                 | 1.2 |                |       |            |        |

**Relative density** : Not available. **Density** : 1.1 g/cm<sup>3</sup> Vapour density : Not available. **Explosive properties** Not available. **Oxidising properties** : Not available.

**Particle characteristics** 

Median particle size : Not applicable.

## SECTION 10: Stability and reactivity

10.1 Reactivity : No specific test data related to reactivity available for this product or its ingredients.

10.2 Chemical stability : The product is stable.

10.3 Possibility of hazardous reactions : Under normal conditions of storage and use, hazardous reactions will not occur.

10.4 Conditions to avoid : Avoid all possible sources of ignition (spark or flame). Do not pressurise, cut, weld,

braze, solder, drill, grind or expose containers to heat or sources of ignition.

: Reactive or incompatible with the following materials: 10.5 Incompatible materials

oxidising materials

10.6 Hazardous decomposition products Under normal conditions of storage and use, hazardous decomposition products should not be produced.

## SECTION 11: Toxicological information

## 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

## **Acute toxicity**

| Product/ingredient name | Result                    | Species | Dose                    | Exposure |
|-------------------------|---------------------------|---------|-------------------------|----------|
| n-Butyl acetate         | LC50 Inhalation Vapour    | Rat     | 0.74 mg/l               | 4 hours  |
| -                       | LD50 Dermal               | Rabbit  | 14112 mg/kg             | -        |
|                         | LD50 Oral                 | Rat     | 10760 mg/kg             | -        |
| Xylene                  | LC50 Inhalation Vapour    | Rat     | 21.7 mg/l               | 4 hours  |
|                         | LD50 Oral                 | Rat     | 4300 mg/kg              | -        |
| 2-Methoxy-1-methylethyl | LD50 Dermal               | Rabbit  | >5 g/kg                 | -        |
| acetate                 |                           |         |                         |          |
|                         | LD50 Oral                 | Rat     | 8532 mg/kg              | -        |
| Ethylbenzene            | LC50 Inhalation Dusts and | Rat     | 29000 mg/l              | 4 hours  |
|                         | mists                     |         |                         |          |
|                         | LD50 Dermal               | Rabbit  | 15400 mg/kg             | -        |
|                         | LD50 Oral                 | Rat     | 3500 mg/kg              | -        |
| 2-butoxyethyl acetate   | LD50 Dermal               | Rabbit  | 1500 mg/kg              | -        |
|                         | LD50 Oral                 | Rat     | 2400 mg/kg              | -        |
| Methyl methacrylate     | LC50 Inhalation Vapour    | Rat     | 78000 mg/m <sup>3</sup> | 4 hours  |
|                         | LD50 Dermal               | Rabbit  | >5 g/kg                 | -        |
|                         | LD50 Oral                 | Rat     | 7872 mg/kg              | -        |

Date of issue/Date of revision : 20/12/2023 Version :1 11/18 Date of previous issue : No previous validation Label No: 68362

## **SECTION 11: Toxicological information**

Conclusion/Summary

: Based on available data, the classification criteria are not met.

**Acute toxicity estimates** 

| Route | ATE value                  |
|-------|----------------------------|
|       | 8216.6 mg/kg<br>69.88 mg/l |

#### **Irritation/Corrosion**

| Product/ingredient name    | Result                   | Species | Score | Exposure      | Observation |
|----------------------------|--------------------------|---------|-------|---------------|-------------|
| n-Butyl acetate            | Eyes - Moderate irritant | Rabbit  | -     | 100 mg        | -           |
|                            | Skin - Moderate irritant | Rabbit  | -     | 24 hours 500  | -           |
|                            |                          |         |       | mg            |             |
| titanium dioxide           | Skin - Mild irritant     | Human   | -     | 72 hours 300  | -           |
|                            |                          |         |       | ug I          |             |
| Xylene                     | Eyes - Mild irritant     | Rabbit  | -     | 87 mg         | -           |
|                            | Eyes - Severe irritant   | Rabbit  | -     | 24 hours 5    | -           |
|                            |                          |         |       | mg            |             |
|                            | Skin - Mild irritant     | Rat     | -     | 8 hours 60 uL | -           |
|                            | Skin - Moderate irritant | Rabbit  | -     | 100 %         | -           |
|                            | Skin - Moderate irritant | Rabbit  | -     | 24 hours 500  | -           |
|                            |                          |         |       | mg            |             |
| Ethylbenzene               | Eyes - Severe irritant   | Rabbit  | -     | 500 mg        | -           |
|                            | Skin - Mild irritant     | Rabbit  | -     | 24 hours 15   | -           |
|                            |                          |         |       | mg            |             |
| 2-butoxyethyl acetate      | Eyes - Mild irritant     | Rabbit  | -     | 24 hours 500  | -           |
|                            |                          |         |       | mg            |             |
|                            | Skin - Mild irritant     | Rabbit  | -     | 500 mg        | -           |
| N,N,4-trimethylpiperazine- | Eyes - Severe irritant   | Rabbit  | -     | 24 hours 750  | -           |
| 1-ethylamine               |                          |         |       | ug            |             |
|                            | Skin - Severe irritant   | Rabbit  | -     | 24 hours 5    | -           |
|                            |                          |         |       | mg            |             |

**Conclusion/Summary** 

Sensitisation

: Causes skin irritation.

**Conclusion/Summary** 

: Based on available data, the classification criteria are not met.

**Mutagenicity** 

**Conclusion/Summary**: Based on available data, the classification criteria are not met.

**Carcinogenicity** 

It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantities leading to significant impairment of particle clearance mechanisms in the lung.

**Conclusion/Summary** 

: Based on available data, the classification criteria are not met.

**Reproductive toxicity** 

**Conclusion/Summary** 

: Based on available data, the classification criteria are not met.

**Teratogenicity** 

**Conclusion/Summary**: Based on available data, the classification criteria are not met.

#### Specific target organ toxicity (single exposure)

| Product/ingredient name   | Category                 | Route of exposure | Target organs                                       |
|---------------------------|--------------------------|-------------------|---|
| n-Butyl acetate<br>Xylene | Category 3<br>Category 3 | -                 | Narcotic effects<br>Respiratory tract<br>irritation |
| Methyl methacrylate       | Category 3               | -                 | Respiratory tract irritation                        |

#### Specific target organ toxicity (repeated exposure)

| Product/ingredient name | Category   | Route of exposure                 | Target organs  |
|-------------------------|------------|-----------------------------------|----------------|
| Xylene                  | Category 2 | oral, inhalation oral, inhalation | -              |
| Ethylbenzene            | Category 2 |                                   | hearing organs |

Date of issue/Date of revision : 20/12/2023 Date of previous issue : No previous validation Version : 1 12/18

**Label No: 68362** 

## SECTION 11: Toxicological information

#### **Aspiration hazard**

| Product/ingredient name | Result  |
|-------------------------|---|
| Xylene<br>Ethylbenzene  | ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1 |

**Information on likely routes**: Not available.

of exposure

Potential acute health effects

**Eye contact** : Causes serious eye irritation.

Inhalation : Can cause central nervous system (CNS) depression. May cause drowsiness or

dizziness.

**Skin contact** : Causes skin irritation.

: Can cause central nervous system (CNS) depression. Ingestion

#### Symptoms related to the physical, chemical and toxicological characteristics

**Eye contact** : Adverse symptoms may include the following:

> pain or irritation watering redness

Inhalation : Adverse symptoms may include the following:

nausea or vomiting

headache

drowsiness/fatique dizziness/vertigo unconsciousness

**Skin contact** : Adverse symptoms may include the following:

> irritation redness

Ingestion : No specific data.

### Delayed and immediate effects as well as chronic effects from short and long-term exposure

**Short term exposure** 

**Potential immediate** : Not available.

effects

**Potential delayed effects** : Not available.

Long term exposure

**Potential immediate** : Not available.

effects

**Potential delayed effects** : Not available.

Potential chronic health effects

Not available.

**Conclusion/Summary** : Not available.

**General** : May cause damage to organs through prolonged or repeated exposure.

Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. **Reproductive toxicity** : No known significant effects or critical hazards.

#### 11.2 Information on other hazards

11.2.1 Endocrine disrupting properties

Not available.

11.2.2 Other information

Not available.

Date of issue/Date of revision : 20/12/2023 Version :1 Date of previous issue : No previous validation Label No: 68362

13/18

## **SECTION 12: Ecological information**

#### 12.1 Toxicity

| Product/ingredient name | Result                                | Species                                    | Exposure |
|-------------------------|---------------------------------------|--|----------|
| n-Butyl acetate         | Acute LC50 32 mg/l Marine water       | Crustaceans - Artemia salina               | 48 hours |
|                         | Acute LC50 18000 µg/l Fresh water     | Fish - Pimephales promelas                 | 96 hours |
| titanium dioxide        | Acute LC50 3 mg/l Fresh water         | Crustaceans - Ceriodaphnia dubia - Neonate | 48 hours |
|                         | Acute LC50 6.5 mg/l Fresh water       | Daphnia - <i>Daphnia pulex</i> - Neonate   | 48 hours |
|                         | Acute LC50 >1000000 μg/l Marine water | Fish - Fundulus heteroclitus               | 96 hours |
| Methyl methacrylate     | Acute LC50 130000 μg/l Fresh water    | Fish - <i>Pimephales promelas</i> - Adult  | 96 hours |

**Conclusion/Summary** 

: Based on available data, the classification criteria are not met.

#### 12.2 Persistence and degradability

**Conclusion/Summary**: This product has not been tested for biodegradation.

#### 12.3 Bioaccumulative potential

| Product/ingredient name         | LogPow | BCF         | Potential |
|---------------------------------|--------|-------------|-----------|
| n-Butyl acetate                 | 2.3    | -           | Low       |
| Xylene                          | 3.12   | 8.1 to 25.9 | Low       |
| 2-Methoxy-1-methylethyl acetate | 1.2    | -           | Low       |
| Ethylbenzene                    | 3.6    | -           | Low       |
| 2-butoxyethyl acetate           | 1.51   | -           | Low       |
| Methyl methacrylate             | 1.38   | -           | Low       |

#### 12.4 Mobility in soil

Soil/water partition coefficient (Koc)

: Not available.

Mobility : Not available.

#### 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

### 12.6 Endocrine disrupting properties

Not available.

#### 12.7 Other adverse effects

No known significant effects or critical hazards.

## **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

#### **Product**

**Methods of disposal** 

: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

Hazardous waste

: The classification of the product may meet the criteria for a hazardous waste.

European waste catalogue (EWC)

: 08.01.11

Date of issue/Date of revision: 20/12/2023Date of previous issue: No previous validationVersion: 114/18ALPOCRYL RF 5364-15 - All variantsLabel No :68362

## SECTION 13: Disposal considerations

#### **Packaging**

Methods of disposal

: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

#### **Special precautions**

This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapour from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

## **SECTION 14: Transport information**

|                                    | ADR/RID  | ADN  | IMDG   | IATA   |
|------------------------------------|--|--|--|--|
| 14.1 UN number or ID number        | UN1993   | UN1993   | UN1993   | UN1993   |
| 14.2 UN proper shipping name       | FLAMMABLE LIQUID,<br>N.O.S. (n-butyl<br>acetate, xylene) | FLAMMABLE LIQUID,<br>N.O.S. (n-butyl<br>acetate, xylene) | FLAMMABLE LIQUID,<br>N.O.S. (xylene,<br>2-methoxy-<br>1-methylethyl acetate) | FLAMMABLE LIQUID,<br>N.O.S. (xylene,<br>2-methoxy-<br>1-methylethyl acetate) |
| 14.3 Transport<br>hazard class(es) | 3  | 3  | 3  | 3  |
| 14.4 Packing group                 | III  | III  | III  | III  |
| 14.5<br>Environmental<br>hazards   | No.  | Yes.   | No.  | No.  |

#### **Additional information**

ADR/RID

Tunnel code (D/E)

**ADN** 

The product is only regulated as an environmentally hazardous substance when

transported in tank vessels.

14.6 Special precautions for

Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

Label No: 68362

14.7 Maritime transport in bulk according to IMO instruments

: Not relevant/applicable due to nature of the product.

## SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

**Annex XIV** 

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Date of issue/Date of revision 15/18 : 20/12/2023 Date of previous issue Version :1 : No previous validation

## **SECTION 15: Regulatory information**

| Product/ingredient name | %   | Designation [Usage] |
|-------------------------|-----|---------------------|
| ALPOCRYL RF 5364-15     | ≥90 | 3                   |

Labelling

Other EU regulations

Industrial emissions : Not listed

(integrated pollution prevention and control) -

Air

Industrial emissions : Not listed

(integrated pollution prevention and control) -

Water

Explosive precursors : Not applicable.

Ozone depleting substances (1005/2009/EU)

Not listed.

Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

**Persistent Organic Pollutants** 

Not listed.

**Seveso Directive** 

This product is controlled under the Seveso Directive.

**Danger criteria** 

Category

P<sub>5</sub>c

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

**Montreal Protocol** 

Not listed.

**Stockholm Convention on Persistent Organic Pollutants** 

Not listed.

**Rotterdam Convention on Prior Informed Consent (PIC)** 

Not listed.

**UNECE Aarhus Protocol on POPs and Heavy Metals** 

Not listed.

15.2 Chemical safety

assessment

: This product contains substances for which Chemical Safety Assessments are still

required.

## **SECTION 16: Other information**

Indicates information that has changed from previously issued version.

Abbreviations and acronyms

: ATE = Acute Toxicity Estimate

CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.

Label No: 68362

1272/2008]

DMEL = Derived Minimal Effect Level
DNEL = Derived No Effect Level

EUH statement = CLP-specific Hazard statement

N/A = Not available

PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration

Date of issue/Date of revision: 20/12/2023Date of previous issue: No previous validationVersion: 116/18

#### **SECTION 16: Other information**

RRN = REACH Registration Number

SGG = Segregation Group

vPvB = Very Persistent and Very Bioaccumulative

#### Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

| Classification      | Justification         |
|---------------------|-----------------------|
| Flam. Liq. 3, H226  | On basis of test data |
| Skin Irrit. 2, H315 | Calculation method    |
| Eye Irrit. 2, H319  | Calculation method    |
| STOT SE 3, H336     | Calculation method    |
| STOT RE 2, H373     | Calculation method    |

#### Full text of abbreviated H statements

| H225   | Highly flammable liquid and vapour.                                |
|--------|--|
| H226   | Flammable liquid and vapour.                                       |
| H302   | Harmful if swallowed.  |
| H304   | May be fatal if swallowed and enters airways.                      |
| H311   | Toxic in contact with skin.  |
| H312   | Harmful in contact with skin.                                      |
| H314   | Causes severe skin burns and eye damage.                           |
| H315   | Causes skin irritation.  |
| H317   | May cause an allergic skin reaction.                               |
| H318   | Causes serious eye damage.   |
| H319   | Causes serious eye irritation.                                     |
| H332   | Harmful if inhaled.  |
| H335   | May cause respiratory irritation.                                  |
| H336   | May cause drowsiness or dizziness.                                 |
| H351   | Suspected of causing cancer.                                       |
| H373   | May cause damage to organs through prolonged or repeated exposure. |
| H412   | Harmful to aquatic life with long lasting effects.                 |
| EUH066 | Repeated exposure may cause skin dryness or cracking.              |

#### Full text of classifications [CLP/GHS]

| Acute Tox. 3      | ACUTE TOXICITY - Category 3                                     |
|-------------------|---|
| Acute Tox. 4      | ACUTE TOXICITY - Category 4                                     |
| Aquatic Chronic 3 | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3                 |
| Asp. Tox. 1       | ASPIRATION HAZARD - Category 1                                  |
| Carc. 2           | CARCINOGENICITY - Category 2                                    |
| Eye Dam. 1        | SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1                  |
| Eye Irrit. 2      | SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2                  |
| Flam. Liq. 2      | FLAMMABLE LIQUIDS - Category 2                                  |
| Flam. Liq. 3      | FLAMMABLE LIQUIDS - Category 3                                  |
| Skin Corr. 1B     | SKIN CORROSION/IRRITATION - Category 1B                         |
| Skin Irrit. 2     | SKIN CORROSION/IRRITATION - Category 2                          |
| Skin Sens. 1      | SKIN SENSITISATION - Category 1                                 |
| STOT RE 2         | SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 2 |
| STOT SE 3         | SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 3   |

Date of issue/ Date of : 20/12/2023

revision

Date of previous issue : No previous validation

Version : 1

ALPOCRYL RF 5364-15 All variants

#### **Notice to reader**

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.

Date of issue/Date of revision : 20/12/2023 Date of previous issue : No previous validation Version : 1 17/18

**Label No: 68362** 

Date of issue/Date of revision: 20/12/2023Date of previous issue: No previous validationVersion: 118/18

ALPOCRYL RF 5364-15 - All variants Label No :68362